J. Wardas et al., SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats, SYNAPSE, 41(2), 2001, pp. 160-171
The aim of the present study was to find out whether blockade of adenosine
A(2A) receptors by a selective antagonist, SCH 58261, influenced parkinsoni
an-like muscle rigidity. Muscle tone was examined using a combined mechano-
and electromyographic method which simultaneously measured muscle resistan
ce (MMG) of a rat hindfoot to passive extension and flexion in the ankle jo
int and electromyographic activity (EMG) of the antagonistic muscles of tha
t joint: gastrocnemius and tibialis anterior. Muscle rigidity produced by r
eserpine (5 mg/kg + alpha -methyl-p-tyrosine, 250 mg/kg) was antagonized by
SCH 58261 (0.1-5 mg/kg). SCH 58261 (5 mg/kg) also reduced reserpine-enhanc
ed tonic and reflex EMG activities in both the gastrocnemius and the tibial
is muscles. Moreover, SCH 58261 in doses of 1 and 5 mg/kg abolished muscle
resistance induced by haloperidol (0.5 mg/kg). However, only the highest do
se of SCH 58261 (5 mg/kg) decreased tonic EMG activity enhanced by haloperi
dol. Administration of L-DOPA (75 and 100 mg/kg) dose-dependently decreased
the muscle resistance as well as tonic EMG activity evoked by haloperidol.
Combined administration of SCH 58261 (0.1 mg/kg) and L-DOPA (50 mg/kg) in
doses which did not affect the haloperidol-induced muscle rigidity produced
a pronounced synergistic effect. The ability of SCH 58261 to diminish the
parkinsonian-like muscle rigidity and to potentiate the effect of L-DOPA in
this model seems to indicate a therapeutic value of this compound in the t
reatment of Parkinson's disease. (C) 2001 Wiley-Liss, Inc.